Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (SCIG03)

• ClinicalTrials.gov Identifier: NCT01884311
• Recruitment Status: Completed
• First Posted: June 24, 2013
• Results First Posted: September 12, 2018
• Last Update Posted: September 12, 2018
• Sponsor: Bio Products Laboratory
• Information provided by (Responsible Party): Bio Products Laboratory

Study Description

Brief Summary:

The main objective of the study is to determine the pharmacokinetics profile of Subgam-VF. The secondary objectives are to assess the safety of Subgam-VF and refine the dose adjustment coefficient for Subgam-VF needed for subjects switching from prior intravenous immunoglobulin (IGIV) therapy.

Condition or disease	Intervention/treatment	Phase
Primary Immune Deficiency Disorders; Common Variable Immunodeficiency; X-linked Agammaglobulinaemia; Hyperimmunoglobulin M Syndrome	Biological: Subgam	Phase 3

Detailed Description:

This will be a Phase III, multicenter, open-label, non-randomized study.

Following a screening period, eligible subjects will commence weekly Subgam-VF treatment; this is a 16% subcutaneous IgG product.

Subjects will receive Subgam-VF for 26 weeks during which time safety will be assessed.

After Week 21, PK sampling will commence.

Follow-up visit (one week after the last Subgam-VF infusion, Week 27). All AEs will be monitored up to 28 days after the last Subgam-VF infusion by telephone contact (Week 30).

Subgam-VF will be administered subcutaneously using infusion pumps.

Subjects will be given diaries to record adverse event data as well as any infusions administered at home. In addition there will be a telephone follow up by an appropriately qualified site staff member on day 3 after each site administered and home administered infusion to check for any adverse reactions including infusion site reactions and remind subjects to document these in their subject study diary.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 38 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases
• Actual Study Start Date: August 20, 2015
• Actual Primary Completion Date: May 25, 2017
• Actual Study Completion Date: May 25, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Subgam-VF; Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.	Biological: Subgam; Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.; Other Name: Subgam-VF

Outcome Measures

Primary Outcome Measures :

1. Data (Derived From Absolute Concentration) Were Pooled With Historical Data and a Treatment Variable Defined (Subgam-VF or Gammaplex 5% IGIV). Outcome Measure Defined as Log Transformed sAUC0-t Standardized to One Week. [ Time Frame: 1 week ]
   Log transformed sAUC0-t, (AUC0-t standardized to one week) were analysed using a multiple linear regression model fitted including treatment, allowing for variability between treatment groups. The mean difference (Subgam-VF or Gammaplex IGIV 5%) between treatments with 90% Confidence Interval (CI) were back transformed to give an estimate of the ratio (Subgam-VF/ Gammaplex 5% IGIV) of sAUC(0-t). Data was collected at the following timepoints after week 21 of the clinical trial over a period of 1 week: Pre-dose on Day 0 and post-dose at days 1, 2, 3, 5 and 7.

Secondary Outcome Measures :

1. Number of Participants Who Experienced AEs Based on Treatment-emergent AEs (TEAEs) [ Time Frame: 30 weeks ]
   TEAEs defined as those events with onset date between the first infusion date and 28 days after the last infusion.
2. Dose Refinement in Switching From Gammaplex 5% IGIV to Subgam-VF [ Time Frame: Week 26 ]

   The initial weekly dose of Subgam-VF administered was calculated by taking the average weekly equivalent of the subject's IGIV dose, divided by the average dosing interval in weeks (i.e. 3 or 4), multiplied by 1.37, a dose adjustment coefficient based on other licensed subcutaneous IgG products. If the subject was already receiving a weekly SCIG IgG there will be no dose adjustment.

   A refined dose adjustment was estimated as 1.37/the ratio (Subgam-VF/ Gammaplex 5% IGIV) of geometric means for sAUC0-t and presented with 90% CI.

3. Number of Infusion Site Reactions [ Time Frame: 30 weeks ]
   Infusion site reactions are defined as those events with onset date between the first infusion date and 28 days after the last infusion.

Other Outcome Measures:

1. Population PK Model for IgG in PID Patients for Alternative Dosing Schedules. [ Time Frame: 30 months ]

   Develop a population pharmacokinetic (PK) model for IgG in PID patients following IV (Gammaplex 5%) or SC (Subgam-VF) administration;

   • Conduct a formal covariate analysis to assess the impact of patient demographics, and disease-related factors on the PK of IgG following IV or SC administration and to identify those patient covariates which may be utilized in or require dose adjustment;

   • Use the final population PK model to simulate serum IgG concentration-time profiles in a population of PID patients in order to:

     • Assess switching from various IgG IV and SC dosing regimens; and
     • Derive the weight-adjusted dose increment required to achieve a specified difference in serum IgG trough levels when Subgam-VF is administered either weekly or biweekly

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 75 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

1. Aged between 2 and 75 years (at time of initial consent).
2. Body Mass Index (BMI) < 46 for adults (aged 16 years & older), & BMI < 28 for children.
3. Diagnosed with primary immunodeficiency disease e.g. common variable immunodeficiency, X-linked & autosomal forms of agammaglobulinaemia, hyper-IgM syndrome, Wiskott-Aldrich syndrome.

4. Currently receiving a licensed (or investigational stage III, IIIb) IGIV or SCIG and

   1. IGIV dose is between 300 and 800 mg/kg/month. SCIG dose is between 110 & 300 mg/kg/week;
   2. Dose is stable for at least the past three months (i.e. consistent mg/kg +/- 5%);
   3. The infusion interval is every 21 or 28 days for IGIV & seven days for SCIG;
   4. Has a documented trough level of ≥ 6 g/L (600 mg/dL) on current IgG therapy. If not available can be obtained at the screening visit, Visit 1 (Week 0).
5. Female subjects who are (or become) sexually active must practice contraception by using a method of proven reliability for the duration of the study.
6. Females of child-bearing potential, (defined from the onset of menstruation to one year post menopause), must have a negative result on a urine HCG-based pregnancy test.
7. Willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
8. Signed an informed consent form. In the case of subjects under the legal age the parent/guardian will sign an informed consent form & where appropriate the subject will sign an assent form.

Exclusion Criteria:

1. Has a history of any severe anaphylactic reaction to blood or any blood-derived product.
2. Has selective IgA deficiency or has a history of antibodies to IgA.
3. Has clinically significant impairment of cellular or innate immunity at the discretion of the Investigator
4. Has evidence of an active infection at the time of enrolment (i.e. on day of first infusion). Subjects who are asymptomatic but have not completed their course of antibiotics are eligible.
5. Has previously completed or withdrawn from this study.
6. Is currently receiving, or has received, any investigational agent within the prior three months, unless it is an investigational stage III, IIIb IGIV or SCIG.
7. Is pregnant (confirmed by a positive result on an HCG-based pregnancy test) or is nursing.

8. Is positive for any of the following at screening:

   • Serological test for HIV 1&2, HCV, or HBsAg

9. Has levels at screening greater than 2.5 times the upper limit of normal as defined at the central laboratory of any of the following:

   • Alanine transaminase (ALT)
   • Aspartate transaminase (AST)
10. Has severe renal impairment (defined as serum creatinine greater than two times the upper limit of normal or BUN greater than two times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; or has a history of acute renal failure.
11. Is known to abuse alcohol, opiates, psychotropic agents, or other chemicals or drugs, or has done so within the past 12 months.
12. Has a history of DVT, or thrombotic complications of IgG therapy, or a prior diagnosis of thrombophilia.
13. Suffers from any acute or chronic medical condition, (e.g. renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing state, proteinuria) that the Investigator feels may interfere with the conduct of the study.
14. Has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (ANC < 1 x 109/L).

15. Is receiving the following medication:

    • Steroids (long-term daily, > 0.15 mg of prednisone equivalent/kg/day). Requirement for short or intermittent courses of > 0.15mg/kg/day would not exclude a subject.
    • Immunosuppressive drugs
    • Immunomodulatory drugs
16. If ≥ 18 years of age, has non-controlled arterial hypertension (systolic blood pressure > 160 mmHg &/or diastolic blood pressure > 100 mmHg). For younger subjects refer to current guidelines for diagnosis of blood pressure1.
17. Has anemia (hemoglobin < 10 g/dL) at screening.
18. Has severe dermatitis that would preclude sites for safe product administration.

Contacts and Locations

Locations

United States, Arizona

Arizona Allergy Associates

Chandler, Arizona, United States, 85224

United States, California

University of California, Irvine

Irvine, California, United States, 92697

University of California San Diego-- Rady's Children's Hospital

San Diego, California, United States, 92123

United States, Colorado

Immunoe International Research

Centennial, Colorado, United States, 80112

United States, Florida

Allergy Associate of the Palm Beaches

North Palm Beach, Florida, United States, 33408

United States, Illinois

Ann and Robert H Lurie Children's Hospital

Chicago, Illinois, United States, 60611

United States, Minnesota

Cardinal Glennon Children's Medical Center

Minneapolis, Minnesota, United States, 63104

United States, Ohio

Optimed Research

Columbus, Ohio, United States, 43235

United States, Oklahoma

Oklahoma Institute of Allergy & Asthma Clinical Research, LLC

Oklahoma City, Oklahoma, United States, 73131

United States, Pennsylvania

Pennsylvania State University

Hershey, Pennsylvania, United States, 174033

United States, Texas

Dallas Allergy Immunology

Dallas, Texas, United States, 75230

AARA Research Center

Dallas, Texas, United States, 75231

United States, Utah

University of Utah

Salt Lake City, Utah, United States, 84112

United States, Virginia

O&O Alpan, LLC

Fairfax, Virginia, United States, 22030

United States, Washington

Bellingham Asthma Allergy Clinic

Bellingham, Washington, United States, 98225

United States, Wisconsin

The Medical College of Wisconsin/Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Sponsors and Collaborators

Bio Products Laboratory

Investigators

• Study Director: Eric Wolford; Bio Products Laboratory Limited

  Study Documents (Full-Text)

Documents provided by Bio Products Laboratory:

Study Protocol  [PDF] March 22, 2017

Statistical Analysis Plan  [PDF] January 12, 2017

More Information

• Responsible Party: Bio Products Laboratory
• ClinicalTrials.gov Identifier: NCT01884311
• Other Study ID Numbers: SCIG03
• First Posted: June 24, 2013
• Results First Posted: September 12, 2018
• Last Update Posted: September 12, 2018
• Last Verified: August 2018

Keywords provided by Bio Products Laboratory:

Primary Immune Deficiency Disorders; Common Variable Immunodeficiency; X-linked agammaglobulinaemia; Hyper-IgM Syndrome; Subcutaneous; Immunoglobulins

Additional relevant MeSH terms:

Agammaglobulinemia; Hyper-IgM Immunodeficiency Syndrome; Primary Immunodeficiency Diseases; Immunologic Deficiency Syndromes; Common Variable Immunodeficiency; Immune System Diseases; Genetic Diseases, Inborn; Blood Protein Disorders; Hematologic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Dysgammaglobulinemia